2010
DOI: 10.1038/aja.2010.114
|View full text |Cite
|
Sign up to set email alerts
|

The complexities of identifying a cell of origin for human prostate cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2011
2011
2016
2016

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 11 publications
0
2
0
Order By: Relevance
“…A debate is ongoing as to which type of epithelial cell represents the cell of origin for PCa: luminal stem cells [ 16 ], basal stem cells [ 17 ], or both [ 18 ]. Given the heterogeneity of the disease and the many genetic pathways that are involved, there is likely a complex explanation [ 19 ]. An understanding of where malignant cells arise from in the prostate may be of vital importance for the development of more effective treatments [ 20 ].…”
Section: Introductionmentioning
confidence: 99%
“…A debate is ongoing as to which type of epithelial cell represents the cell of origin for PCa: luminal stem cells [ 16 ], basal stem cells [ 17 ], or both [ 18 ]. Given the heterogeneity of the disease and the many genetic pathways that are involved, there is likely a complex explanation [ 19 ]. An understanding of where malignant cells arise from in the prostate may be of vital importance for the development of more effective treatments [ 20 ].…”
Section: Introductionmentioning
confidence: 99%
“…Malignant cells derived from prostate epithelial layers of PCa, which include secretory luminal, basal, and rare neuroendocrine cells, lend to disease a high grade of heterogeneity [ 9 ]. A question is pending about which type of epithelial cell represents the origin of PCa: luminal stem cells, basal stem cells, or both [ 14 ]; this point still remains unclear, but it is likely that there is a complex explanation of the heterogeneity of the disease and the many genetic pathways that are involved [ 15 ]. Despite the incidence rate trend in PCa, which continues to fall by 3-4% each year, and a large amount of prostate cancer studies, only very few findings have influenced the clinical management of the disease.…”
Section: Introductionmentioning
confidence: 99%